NCT04853030已完成不适用
A Double-blind, Multinational, Multicentre, Randomised, 2-period Crossover Study to Assess the Efficacy and Safety of Advanced Closed-loop Insulin Delivery With Minimed 670 4.0 System Comparing Faster Insulin Aspart to Standard Insulin Aspart Therapy Over 4 Weeks in Active Children and Adolescents With Type 1 Diabetes - the FACT Study
University of Ljubljana, Faculty of Medicine2 个研究点 分布在 2 个国家目标入组 30 人开始时间: 2021年4月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Time above range 180 mg/dl
研究概览
简要总结
A double-blind, multinational, multicenter, randomised, 2-period crossover study to assess the efficacy and safety of advanced closed-loop insulin delivery with Minimed 670G 4.0 system comparing Faster Insulin Aspart to Standard Insulin Aspart therapy over 4 weeks in active children and adolescents with type 1 diabetes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Blinded insulin formulation (Faster and Standard Insulin Aspart)
入排标准
- 年龄范围
- 10 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 10 and 18 years of age
- •Type 1 diabetes for at least 6 months
- •Insulin pump user for at least 3 months
- •Total daily dose of insulin >8 units/day
- •Treated with rapid acting insulin analogue
- •Subject/carer is willing to perform at least 2 finger-prick blood glucose measurements per day
- •Screening HbA1c ≤ 11 % (97 mmol/mol) based on analysis from local laboratory
- •Willing to wear glucose sensor
- •Willing to wear closed loop system 24/7
- •The subject is willing to follow study specific instructions
- •The subject/carer is willing to upload pump and CGM data at regular intervals
排除标准
- •Physical or psychological disease likely to interfere with normal conduct of the study
- •Untreated coeliac disease or thyroid disease
- •Current treatment with drugs known to interfere with glucose metabolism
- •Participation in another interventional clinical investigation
- •Treated with ultra-rapid acting insulin analogue
- •Known or suspected allergy to insulin
- •Carer's lack of reliable telephone facility for contact
- •Subject's severe visual impairment
- •Subject's severe hearing impairment
- •Medically documented allergy towards the adhesive (glue) of plasters or subject is unable to tolerate tape adhesive in the area of sensor placement
- •Serious skin diseases located at places of the body corresponding with sensor insertion sites
- •Sickle cell disease, haemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening
研究组 & 干预措施
Minimed 670G 4.0 closed loop with Faster Insulin aspart
Experimental
干预措施: Fiasp (Drug)
Minimed 670G 4.0 closed loop with Standard Insulin aspart
Active Comparator
干预措施: Novorapid (Drug)
结局指标
主要结局
Time above range 180 mg/dl
时间窗: 12 weeks for each arm of the crossover
The primary outcomes is a difference in CGM-measured metrics between periods (Minimed 670G 4.0 closed loop with Faster Insulin aspart and Minimed 670G 4.0 closed loop with Standard Insulin aspart) in superiority for proportion of time \>180 mg/dL (10.0 mmol/L)
次要结局
- Time in range 70-180 mg/dl(4 weeks for each arm of the crossover)
- Time below range <70 mg/dl(4 weeks for each arm of the crossover)
- Mean glucose(4 weeks for each arm of the crossover)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.Postmenopausal Women With OsteoporosisNCT05338086mAbxience Research S.L.558
撤回
2 期
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityRelapsing Multiple SclerosisNCT01404117Teva Branded Pharmaceutical Products R&D, Inc.
已完成
2 期
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)Acute PyelonephritisComplicated Urinary Tract InfectionNCT01096849Achaogen, Inc.145
已完成
1 期
Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisPancreatic InsufficiencyDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesCystic FibrosisNCT01710644Nordmark Arzneimittel GmbH & Co. KG35
进行中（未招募）
不适用
Treatment of Knee Osteoarthritis With PAAG-OAOsteoarthritis, KneeNCT04045431Contura238